| Code | CSB-RA004936MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Iscalimab, designed to target CD40, a costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is predominantly expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, where it plays a critical role in regulating immune responses through interaction with its ligand CD40L. The CD40-CD40L pathway is essential for B cell activation, antibody class switching, germinal center formation, and T cell priming. Dysregulation of this pathway has been implicated in various autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease, as well as in transplant rejection and certain hematological malignancies.
Iscalimab is a fully humanized IgG1 monoclonal antibody that blocks CD40-CD40L interactions, demonstrating immunomodulatory properties in clinical development for autoimmune conditions. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune mechanisms, exploring therapeutic interventions in autoimmune disease models, and studying B cell and T cell interactions in various immunological contexts.
There are currently no reviews for this product.